269 related articles for article (PubMed ID: 20664990)
1. Natural killer-like T CD3+/CD16+CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome.
Bojarska-Junak A; Hus I; Sieklucka M; Wasik-Szczepanek E; Mazurkiewicz T; Polak P; Dmoszynska A; Rolinski J
Oncol Rep; 2010 Sep; 24(3):803-10. PubMed ID: 20664990
[TBL] [Abstract][Full Text] [Related]
2. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications.
García-Sanz R; González M; Orfão A; Moro MJ; Hernández JM; Borrego D; Carnero M; Casanova F; Bárez A; Jiménez R; Portero JA; San Miguel JF
Br J Haematol; 1996 Apr; 93(1):81-8. PubMed ID: 8611480
[TBL] [Abstract][Full Text] [Related]
3. Morphological variants of leukemic cells in B chronic lymphocytic leukemia are associated with different T cell and NK cell abnormalities.
Reyes E; Prieto A; Carrion F; Garcia-Suarez J; Esquivel F; Alvarez-Mon M
Am J Hematol; 1997 Aug; 55(4):175-82. PubMed ID: 9257876
[TBL] [Abstract][Full Text] [Related]
4. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.
Krijgsman D; de Vries NL; Skovbo A; Andersen MN; Swets M; Bastiaannet E; Vahrmeijer AL; van de Velde CJH; Heemskerk MHM; Hokland M; Kuppen PJK
Cancer Immunol Immunother; 2019 Jun; 68(6):1011-1024. PubMed ID: 31053876
[TBL] [Abstract][Full Text] [Related]
5. [Percentages and functions of natural killer cell subsets in peripheral blood of patients with severe aplastic anemia].
Li ZS; Shao ZH; Fu R; Wang J; Li LJ; Zhang T; Wang HQ; Wu YH; Ruan EB; Song J; Qu W; Liu H; Xing LM; Wang XM; Liang Y; Guan J; Wang GJ
Zhonghua Yi Xue Za Zhi; 2011 Apr; 91(16):1084-7. PubMed ID: 21609587
[TBL] [Abstract][Full Text] [Related]
6. Patterns of CD16 and CD56 expression in persistent expansions of CD3+NKa+ lymphocytes are predictive for clonal T-cell receptor gene rearrangements. The Yorkshire Leukaemia Group.
Sivakumaran M; Richards SJ; Hunt KM; Steed AJ; Bynoe AG; Morgan MM; Pyrah R; Roberts BE; Scott CS
Br J Haematol; 1991 Jul; 78(3):368-77. PubMed ID: 1714758
[TBL] [Abstract][Full Text] [Related]
7. Definition of a natural killer NKR-P1A+/CD56-/CD16- functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12.
Bennett IM; Zatsepina O; Zamai L; Azzoni L; Mikheeva T; Perussia B
J Exp Med; 1996 Nov; 184(5):1845-56. PubMed ID: 8920872
[TBL] [Abstract][Full Text] [Related]
8. Proliferative and cytotoxic capabilities of CD16+CD56- and CD16+/-CD56+ natural killer cells.
Søndergaard SR; Ullum H; Pedersen BK
APMIS; 2000 Dec; 108(12):831-7. PubMed ID: 11252817
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo expansion of CD56+ NK and NKT-like lymphocytes from peripheral blood mononuclear cells of patients with ovarian neoplasia.
Alves PCM; De Angelo Andrade LAL; Petta CA; Lorand-Metze I; Derchain SF; Guimarães F
Scand J Immunol; 2011 Sep; 74(3):244-252. PubMed ID: 21595734
[TBL] [Abstract][Full Text] [Related]
11. Comparison of bone marrow and peripheral blood ZAP-70 status examined by flow cytometric immunophenotyping in patients with chronic lymphocytic leukemia.
Sheridan R; Mounajjed T; Ehrmann DE; Hurtubise PE; Schrager JA
Cytometry B Clin Cytom; 2006 Jul; 70(4):320-1. PubMed ID: 16906578
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
Parrado A; Casares S; Rodríguez-Fernández JM
Leuk Res; 1994 Mar; 18(3):191-7. PubMed ID: 7511191
[TBL] [Abstract][Full Text] [Related]
13. CD3(+)CD56(+) Natural Killer-Like T Cells Display Anti-HCV Activity but Are Functionally Impaired in HIV(+) Patients With Acute Hepatitis C.
Kokordelis P; Krämer B; Boesecke C; Voigt E; Ingiliz P; Glässner A; Wolter F; Srassburg CP; Spengler U; Rockstroh JK; Nattermann J
J Acquir Immune Defic Syndr; 2015 Dec; 70(4):338-46. PubMed ID: 26509931
[TBL] [Abstract][Full Text] [Related]
14. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
[TBL] [Abstract][Full Text] [Related]
15. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
[TBL] [Abstract][Full Text] [Related]
16. CD3+/CD16+CD56+ cell numbers in peripheral blood are correlated with higher tumor burden in patients with diffuse large B-cell lymphoma.
Hus I; Starosławska E; Bojarska-Junak A; Dobrzyńska-Rutkowska A; Surdacka A; Wdowiak P; Wasiak M; Kusz M; Twardosz A; Dmoszyńska A; Roliński J
Folia Histochem Cytobiol; 2011; 49(1):183-7. PubMed ID: 21526506
[TBL] [Abstract][Full Text] [Related]
17. Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells.
Smolej L; Vroblova V; Motyckova M; Jankovicova K; Schmitzova D; Krejsek J; Maly J
Neoplasma; 2011; 58(2):140-5. PubMed ID: 21275464
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric visualisation of cytokine production by CD3-CD56+ NK cells and CD3+CD56+ NK-T cells in whole blood.
Mendes R; Bromelow KV; Westby M; Galea-Lauri J; Smith IE; O'Brien ME; Souberbielle BE
Cytometry; 2000 Jan; 39(1):72-8. PubMed ID: 10655565
[TBL] [Abstract][Full Text] [Related]
19. The presence of CD56/CD16 in T-cell acute lymphoblastic leukaemia correlates with the expression of cytotoxic molecules and is associated with worse response to treatment.
Dalmazzo LF; Jácomo RH; Marinato AF; Figueiredo-Pontes LL; Cunha RL; Garcia AB; Rego EM; Falcão RP
Br J Haematol; 2009 Jan; 144(2):223-9. PubMed ID: 19016721
[TBL] [Abstract][Full Text] [Related]
20. Reduction in CD16/CD56 and CD16/CD3/CD56 Natural Killer Cells in Coronary Artery Disease.
Jabir NR; Firoz CK; Ahmed F; Kamal MA; Hindawi S; Damanhouri GA; Almehdar HA; Tabrez S
Immunol Invest; 2017 Jul; 46(5):526-535. PubMed ID: 28414590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
